Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Acarbose
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Tolerability of Acarbose in Healthy Individuals
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : Acarbose
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study for Acarbose/Metformin FDC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2019
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2017
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study for Acarbose / Metformin FDC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2012
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2012
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2011
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Diabetes Intervention Program
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2011
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2011
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2011
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : The Swedish Research Council | Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Exercise and Acarbose in Type 2 Diabetes
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2010
Lead Product(s) : Acarbose
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : The Swedish Research Council | Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable